An orally available small molecule BCL6 inhibitor effectively suppresses diffuse large B cell lymphoma cells growth in vitro and in vivo
Source : https://www.sciencedirect.com/science/article/abs/pii/S0304383521006583?via=ihub
WK500B exhibits potent efficacy against DLBCL in vitro and in vivo. * WK500B shows favourable pharmacokinetic and presents superior druggability. * WK500B could be a promising therapeutic drug candidate for DLBCL. The transcription factor B cell lymphoma 6 (BCL6) is an oncogenic driver of diffuse large B cell lymphoma (DLBCL) and mediates lymphomagenesis through transcriptional repression of its target genes by recruiting corepressors to its N-terminal broad-complex/tramtrack/bric-a-brac (BTB) domain.
Conclusion/Relevance: WK500B is a promising candidate that could be developed as an effective orally available therapeutic agent for DLBCL.